Navigation Links
Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,,and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology -

NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from a Phase II study - which will be published in the August 10, 2007 issue of the Journal of Clinical Oncology (JCO) and are now available as an Early Release Article at www.jco.org - demonstrate that ixabepilone, a Bristol-Myers Squibb Company investigational compound, has activity in patients with metastatic breast cancer whose tumors were resistant to three types of standard chemotherapy (anthracycline, taxane, and capecitabine). Currently, there are few proven treatment options available to patients with breast cancer whose disease has rapidly progressed through or whose disease is not responding to prior treatment with approved chemotherapies. This study was one of five Phase II ixabepilone studies published in this issue of JCO, including three additional studies in metastatic breast cancer and one in non-small cell lung cancer.

"Drug resistance is a major concern in treating patients with advanced disease," said Renzo Canetta, vice president, Oncology Global Clinical Research, Bristol-Myers Squibb. "The results of this study are important as they provide valuable information about this investigational compound and its potential in patients with advanced breast cancer that is no longer responding to any of the current U.S. approved chemotherapy treatments."

The 126 patients enrolled in the single-arm Phase II study (CA163081) had heavily pretreated, advanced metastatic breast cancer, which had progressed through three prior therapies (anthracycline, taxane and capecitabine). The primary endpoint was objective response rate, which is an assessment of the response to treatment as determined by the independent radiology facility (IRF). Secondary efficacy endpoints included duration of response, time to response, progres
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Electrocardiogram (ECG) Devices - Global Trends, Estimates ... http://photos.prnewswire.com/prnh/20130307/600769 Global ... million by 2016. The North America ... market share while Europe claims ...
(Date:12/15/2014)... , December 15, 2014 BerGenBio ... for aggressive drug resistant cancers, today announces that it ... private placing from new and existing investors. ... support the development of its pipeline of innovative cancer ... its lead drug candidate, BGB324, a first-in-class selective Axl ...
(Date:12/15/2014)... and BRIDGEWATER, N.J. , Dec. 15, ... Sanofi US (EURONEXT: SAN and NYSE: SNY) are collaborating ... launch Cholesterol Counts , an awareness program that ... numbers, and the risks associated with high LDL-C (bad ... CholesterolCounts .com to take a brief poll and ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
... HORSHAM, Pa. , July 28 Teva Respiratory ... efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol ... all efficacy endpoints, demonstrating a statistically significant benefit as compared to ... similar to placebo. , , ...
... BOCA RATON, Fla. , July 28 ... Pharma, the company will market Methylphenidate Solution, the generic ... an Abbreviated New Drug Application (ANDA).  Under the terms ... Tris Pharma, and marketed and distributed by Breckenridge on ...
Cached Medicine Technology:Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 2Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 3Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 4Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 5Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 6Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ) 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... ... 2009. , ... October 16, 2009 -- Tony Rico has recently been promoted to Senior Vice President of ... promotion was effective September 1, 2009. , , , , ,"This position has ...
... A bioethicist who specializes in moral dilemmas families face ... honored with the first-ever March of Dimes Distinguished Lectureship ... a nationally-recognized pediatrician and ethicist, will deliver his lecture ... the American Society of Bioethics and Humanities, 11th annual ...
... Feature Gena Rowlands , EAST BRUNSWICK, N.J., Oct. 15 ... home to New Jersey to host a celebrity cocktail reception ... will raise money for National MS Society,s New Jersey Metro ... Jersey, where it is estimated that almost 10,000 people have ...
... 15 ResMed Inc. (NYSE: RMD ), announced today that ... the first quarter of fiscal year 2010, ended September 30, 2009. ... p.m. Pacific Time and the Company will host a conference call ... , The conference call is scheduled to begin at 1:30 p.m. ...
... AUSTIN, Texas, Oct. 15 deverus, inc., a ... for background screening companies, announced today that Corporate ... deverus, Verocity 2009 software platform to provide an ... An affiliate of Corporate Research and Investigations (Pvt.) ...
... WASHINGTON, Oct. 15 A National Awareness Campaign to ... Arabia to coincide with international Breast Cancer Awareness month. The campaign ... of the Zahra Breast Cancer Association and wife of the ... , and Princess Rima bint Abdullah bin Abdulaziz. It officially ...
Cached Medicine News:Health News:Jackson & Coker Promotes Tony Rico to Senior VP of Operations 2Health News:March of Dimes Establishes Two New Perinatal Bioethics Awards 2Health News:March of Dimes Establishes Two New Perinatal Bioethics Awards 3Health News:East Brunswick Native Returns Home to Help New Jersey Residents Living with MS 2Health News:ResMed Announces Conference Call and Webcast to Discuss First Quarter 2010 Results 2Health News:deverus(TM) Expands Operations Overseas 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: